Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Operating Income Loss of -$192.02 million for the year ending 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +27.7% in Operating Income Loss from 2024 to 2025.
- This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: -$6.40 million | Q1 2017: -$6.39 million | Q2 2017: -$6.75 million | Q3 2017: -$8.29 million | Q1 2018: -$17.00 million | Q2 2018: -$15.02 million | Q3 2018: -$19.24 million | Q1 2019: -$30.52 million | Q2 2019: -$44.15 million | Q3 2019: -$37.11 million | Q1 2020: -$35.30 million | Q2 2020: -$31.92 million | Q3 2020: -$34.28 million | Q1 2021: -$34.40 million | Q2 2021: -$40.43 million | Q3 2021: -$44.24 million | Q1 2022: -$52.69 million | Q2 2022: -$45.10 million | Q3 2022: -$39.27 million | Q1 2023: -$52.53 million | Q2 2023: -$46.60 million | Q3 2023: -$43.95 million | Q1 2024: -$139.89 million | Q2 2024: -$40.48 million | Q3 2024: -$43.89 million | Q1 2025: -$47.00 million | Q2 2025: -$45.30 million | Q3 2025: -$52.65 million.
- Over the full 11 years of available data (2015 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 1,716.1%.
- Historical annual values: Fiscal year 2025: -$192.02 million | Fiscal year 2024: -$265.50 million | Fiscal year 2023: -$184.36 million | Fiscal year 2022: -$179.16 million | Fiscal year 2021: -$170.06 million | Fiscal year 2020: -$136.58 million | Fiscal year 2019: -$146.00 million | Fiscal year 2018: -$78.42 million | Fiscal year 2017: -$32.41 million | Fiscal year 2016: -$25.91 million | Fiscal year 2015: -$10.57 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: